Trials / Completed
CompletedNCT01347671
Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- Tris Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GRT6005 | 25µg/day once daily |
| DRUG | GRT6005 | 75 µg/day once daily |
| DRUG | GRT6005 | 200 µg/day once daily |
| DRUG | Matching Placebo | Once daily |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2011-05-04
- Last updated
- 2021-07-15
Locations
22 sites across 3 countries: Bulgaria, Germany, Romania
Source: ClinicalTrials.gov record NCT01347671. Inclusion in this directory is not an endorsement.